Topoisomerase II and the Response to Antileukemic Therapy
- 1 January 1998
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 29 (3-4) , 217-237
- https://doi.org/10.3109/10428199809068560
Abstract
A number of recent studies have investigated the expression of topoisomerase II in clinical leukemia specimens. Here we outline the rationale for these studies, identify potential pitfalls, summarize recent results, and discuss unanswered questions in this area.Keywords
This publication has 55 references indexed in Scilit:
- Biology of the multidrug resistance-associated protein, MRPEuropean Journal Of Cancer, 1996
- Structure and mechanism of DNA topoisomerase IINature, 1996
- Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: A further pitfall in the use of the MTT assay for evaluating cell growth and survivalEuropean Journal Of Cancer, 1993
- In vitro assays for antitumour activity: More pitfalls to come?European Journal Of Cancer, 1993
- Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymesExperimental Cell Research, 1992
- Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase IIBiochemistry, 1991
- Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiaeJournal of Molecular Biology, 1989
- Topoisomerase-II activity in human leukemic and lymphoblastoid cellsBiochemical and Biophysical Research Communications, 1985
- DNA topoisomerase activities in concanavalin A‐stimulated lymphocytesFEBS Letters, 1984
- Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationshipBiochemistry, 1984